Advocacy groups cite bias in India intellectual property effort

A collection of advocacy groups have come together to challenge a series of conferences being offered in India on pharma intellectual property issues. The conferences, which are backed by drugmakers, law firms and the George Washington University Law School, are part of an effort known as the India Project.  While the discussions are billed as neutral forums, the groups claim that the effort does more to protect U.S. IP interests than offer balanced academic discussions. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.